Breaking News Instant updates and real-time market news.

VYGR

Voyager Therapeutics

$13.59

-0.39 (-2.79%)

, RGNX

Regenxbio

08:06
11/29/16
11/29
08:06
11/29/16
08:06

Voyager Therapeutics exercises options for rights to REGENXBIO NAV vectors

Voyager Therapeutics (VYGR) and REGENXBIO (RGNX) announced that Voyager has exercised commercial options for the use of REGENXBIO's NAV vectors for the development and commercialization of gene therapies for specific neurological diseases. Upon exercise of the options, REGENXBIO has granted Voyager a non-exclusive worldwide commercial license, with rights to sublicense, to three specific NAV vector sequences covered by REGENXBIO's NAV Technology Platform, each for the treatment of a specific neurological disease. In return for these rights, REGENXBIO will receive undisclosed upfront payments, ongoing fees, milestone payments and royalties on net sales of products incorporating the licensed intellectual property.

VYGR

Voyager Therapeutics

$13.59

-0.39 (-2.79%)

RGNX

Regenxbio

  • 29

    Nov

VYGR Voyager Therapeutics
$13.59

-0.39 (-2.79%)

01/25/16
01/25/16
UPGRADE

On The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: American Express (AXP) upgraded to Perform from Underperform at Oppenheimer... BankMutual (BKMU) upgraded to Outperform from Market Perform at Hovde Group... Black Hills (BKH) upgraded on acquisition at BMO Capital... Bruker (BRKR) upgraded to Buy from Hold at Cantor... Cedar Fair (FUN) upgraded to Conviction Buy from Buy at Goldman... Charles Schwab (SCHW) upgraded to Buy from Neutral at Nomura... Corporate Office Properties (OFC) upgraded to Buy from Neutral at Mizuho... Entegris (ENTG) upgraded on valuation, outlook at Pacific Crest... First Financial upgraded to Outperform from Market Perform at Keefe Bruyette... Goldman Sachs (GS) upgraded to Buy from Neutral at Nomura... Graphic Packaging (GPK) upgraded to Outperform from Neutral at Macquarie... Home Depot (HD) upgraded to Buy from Hold at Deutsche Bank... Intel (INTC) upgraded to Outperform from Neutral at Macquarie... J.B. Hunt (JBHT) upgraded to Buy from Hold at BB&T... Magna (MGA) upgraded to Buy from Neutral at Citi... Masco (MAS) upgraded to Buy from Hold at Evercore ISI... Mattel (MAT) upgraded to Conviction Buy from Buy at Goldman... O'Reilly Automotive (ORLY) upgraded to Buy from Hold at Deutsche Bank... PACCAR (PCAR) upgraded to Buy from Neutral at Citi... People's United (PBCT) upgraded to Neutral from Underweight at Piper Jaffray... Quality Systems (QSII) upgraded to Overweight from Neutral at Piper Jaffray... RadiSys (RSYS) upgraded to Buy from Hold at Needham... Standard Motor (SMP) upgraded to Buy from Neutral at CL King... Swedbank (SWDBY) upgraded to Hold from Underperform at Jefferies... Toll Brothers (TOL) upgraded to Strong Buy from Outperform at Raymond James... Voyager Therapeutics (VYGR) upgraded to Neutral from Sell at Chardan... Yahoo (YHOO) upgraded to Buy from Hold at Pivotal Research.
05/20/16
WELS
05/20/16
INITIATION
WELS
Outperform
Voyager Therapeutics initiated with an Outperform at Wells Fargo
Target $35-$43.
06/22/16
PIPR
06/22/16
NO CHANGE
Target $37
PIPR
Overweight
Voyager interim data bodes well for clinical outcome, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer said the interim Phase 1B results for VY-AADC01 in Parkinson's Disease build on the prior patients' data from this cohort and bode well for the full six-month data that is expected to be released by year end. The analyst, who notes that Voyager Therapeutics also has 6 preclinical programs beyond the Parkinson's gene therapy program, reiterates an Overweight rating and $37 price target on the stock.
07/14/16
STFL
07/14/16
INITIATION
Target $33
STFL
Buy
Voyager Therapeutics initiated with a Buy at Stifel
Target $33.
RGNX Regenxbio

12/30/15
CHDN
12/30/15
NO CHANGE
Target $35
CHDN
Buy
REGENXBIO news a clear positive, says Chardan
Chardan analyst Gbolahan Amusa raised his price target for REGENXBIO shares to $35 from $33 after the FDA granted Rare Pediatric Disease Designation to RGX-111, the company's investigational gene therapy product candidate for the treatment of mucopolysaccharidosis Type I. The designation could lead to a Rare Pediatric Disease Priority Review Voucher, which could be worth up to $8 per share, Amusa tells investors in a research note. The analyst keeps a Buy rating on the stock.
01/07/16
PIPR
01/07/16
NO CHANGE
Target $33
PIPR
Overweight
REGENXBIO pipeline expanding faster than expected, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer said REGENXBIO's corporate updates released this morning show that its preclinical pipeline is expanding faster than he'd expected. The analyst continues to think that this year will include relevant newsflow for REGENXBIO as the company's vectors progress toward clinical development and keeps an Overweight rating on shares, but trimmed his price target to $33 from $36 to account for the company's guidance for a 2016 cash burn of $60M-$70M.

TODAY'S FREE FLY STORIES

AZO

AutoZone

$535.19

-28.21 (-5.01%)

05:26
09/20/17
09/20
05:26
09/20/17
05:26
Recommendations
AutoZone analyst commentary  »

AutoZone results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 30

    Oct

AGN

Allergan

$215.00

-6.54 (-2.95%)

05:21
09/20/17
09/20
05:21
09/20/17
05:21
Recommendations
Allergan analyst commentary  »

Allergan pipeline largely…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

TRVG

trivago

$10.99

-0.11 (-0.99%)

05:15
09/20/17
09/20
05:15
09/20/17
05:15
Recommendations
trivago analyst commentary  »

trivago price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

05:12
09/20/17
09/20
05:12
09/20/17
05:12
Recommendations
Bed Bath & Beyond analyst commentary  »

Bed Bath & Beyond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLRN

Acceleron

$38.97

-0.41 (-1.04%)

05:10
09/20/17
09/20
05:10
09/20/17
05:10
Recommendations
Acceleron analyst commentary  »

Acceleron price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

ICPT

Intercept

$96.20

0.45 (0.47%)

05:01
09/20/17
09/20
05:01
09/20/17
05:01
Recommendations
Intercept analyst commentary  »

Intercept recent pullback…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YAHOY

Yahoo Japan

$9.02

-0.03 (-0.33%)

04:57
09/20/17
09/20
04:57
09/20/17
04:57
Downgrade
Yahoo Japan rating change  »

Yahoo Japan downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPZM

Epizyme

$19.25

1.4 (7.84%)

04:56
09/20/17
09/20
04:56
09/20/17
04:56
Initiation
Epizyme initiated  »

Epizyme initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 27

    Sep

CSGP

CoStar Group

$280.60

3.97 (1.44%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
CoStar Group management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

YEXT

Yext

$12.99

-0.27 (-2.04%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Yext management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

FCFS

First Cash Financial

$60.65

0.65 (1.08%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
First Cash Financial management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

  • 22

    Sep

VNRX

VolitionRx

$2.75

0.07 (2.61%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
VolitionRx management to meet with Oppenheimer »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 28

    Sep

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Citigroup to hold a conference »

2017 SMID and Travel…

SRCL

Stericycle

$70.19

-0.81 (-1.14%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Stericycle management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

  • 27

    Sep

FIVN

Five9

$22.17

0.31 (1.42%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Five9 management to meet with Roth Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 25

    Sep

GMS

GMS Inc.

$33.50

-0.38 (-1.12%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
GMS Inc. management to meet with Seaport Global »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

HRTG

Heritage Insurance

$11.83

-0.72 (-5.74%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Heritage Insurance management to meet with Sandler O'Neill »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

HZNP

Horizon Pharma

$12.10

0.26 (2.20%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Horizon Pharma management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

OHI

Omega Healthcare

$32.53

-0.12 (-0.37%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Omega Healthcare management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

MZDAF

Mazda

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Mazda management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

SFS

Smart & Final Stores

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Smart & Final Stores management to meet with Loop Capital »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

SRCI

SRC Energy

$8.18

0.16 (2.00%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
SRC Energy management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 25

    Sep

  • 16

    May

AITB

AIT Therapeutics

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
AIT Therapeutics management to meet with Roth Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 26

    Sep

ARLP

Alliance Resource Partners

$18.90

-0.05 (-0.26%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Alliance Resource Partners management to meet with MKM Partners »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

EMR

Emerson

$63.21

0.22 (0.35%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Emerson management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.